Company research
Biomea Fusion, Inc.
CIK 1840439Updated Sep 26, 2026
SecurityBMEA · NASDAQ · equity
BMEA price & chart
Loading TradingView…
NASDAQ:BMEA on TradingView ↗About the company
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
In the news
Biomea Fusion Announces Proposed Public Offering of Securities ↗
Recent filings
424B5 filing
Other Events
Items 8.01
10-Q filing
Financial Statements and Exhibits
Items 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
DEF 14A filing
ARS filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 58,572,000Source | 79,938,000Source | 199,927,000Source | 129,307,000Source |
| Property, Plant and Equipment, NetUSD | 153,000Source | 3,766,000Source | 5,159,000Source | 5,841,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 55,812,000Source | 58,279,000Source | 176,866,000Source | 111,899,000Source |
| Assets, CurrentUSD | 58,050,000Source | 68,332,000Source | 179,181,000Source | 117,819,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,238,000Source | 10,053,000Source | 2,315,000Source | 4,770,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 6,852,000Source | 9,714,000Source | 2,151,000Source |
| Other Assets, NoncurrentUSD | 0Source | 619,000Source | 5,503,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 29,020,000Source | 28,365,000Source | 30,690,000Source | 20,768,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 7,000Source | 4,000Source | 4,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 478,593,000Source | 438,820,000Source | 418,058,000Source | 240,107,000Source |
| Retained Earnings (Accumulated Deficit)USD | -449,048,000Source | -387,251,000Source | -248,825,000Source | -131,570,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | -1,000Source |
| Stockholders' Equity Attributable to ParentUSD | 29,552,000Source | 51,573,000Source | 169,237,000Source | 108,539,000Source |
| Liabilities and EquityUSD | 58,572,000Source | 79,938,000Source | 199,927,000Source | 129,307,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,101,000Source | 21,673,000Source | 22,860,000Source | 19,101,000Source |
| Operating Lease, Liability, CurrentUSD | 1,461,000Source | 2,079,000Source | 2,466,000Source | 618,000Source |
| Accounts Payable, CurrentUSD | 3,233,000Source | 12,932,000Source | 6,851,000Source | 6,826,000Source |
| Operating Lease, Liability, NoncurrentUSD | 128,000Source | 6,692,000Source | 7,830,000Source | 1,667,000Source |
| Additional Financial Items | ||||
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source |
| Short-term InvestmentsUSD | — | — | — | 1,150,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -61,797,000Source | -138,426,000Source | -117,255,000Source | -81,828,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,520,000Source | 19,094,000Source | 14,131,000Source | 10,336,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -9,700,000Source | 6,088,000Source | 2,562,000Source | 2,960,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -70,371,000Source | -119,894,000Source | -96,592,000Source | -62,417,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | -362,000Source | -2,220,000Source | 27,341,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 362,000Source | 3,370,000Source | 1,030,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 67,904,000Source | 1,668,000Source | 163,798,000Source | 1,239,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -2,467,000Source | -118,588,000Source | 64,986,000Source | -33,837,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 56,181,000Source | 58,648,000Source | 177,236,000Source | 112,250,000Source |
| Additional Financial Items | ||||
| DepreciationUSD | 1,409,000Source | 1,748,000Source | 1,515,000Source | 691,000Source |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | 19,328,000Source | 25,985,000Source | 23,589,000Source | 20,921,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -61,797,000Source | -138,426,000Source | -117,255,000Source | -81,828,000Source |
| Operating ExpensesUSD | 83,512,000Source | 144,070,000Source | 126,135,000Source | 83,634,000Source |
| Proceeds from Issuance of Common StockUSD | 4,908,000Source | — | 161,803,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -83,512,000Source | -144,070,000Source | -126,135,000Source | -83,634,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -61,797,000Source | -138,426,000Source | -117,255,000Source | -81,828,000Source |
| Earnings Per Share, BasicUSD per share | -1.18Source | -3.83Source | -3.44Source | -2.8Source |
| Earnings Per Share, DilutedUSD per share | -1.18Source | -3.83Source | -3.44Source | -2.8Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 52,228,068Source | 36,105,671Source | 34,106,923Source | 29,271,777Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 52,228,068Source | 36,105,671Source | 34,106,923Source | 29,271,777Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 19,328,000Source | 25,985,000Source | 23,589,000Source | 20,921,000Source |
| Interest and Other IncomeUSD | 1,858,000Source | 5,644,000Source | 8,880,000Source | 1,806,000Source |
| Interest Income (Expense), NetUSD | 1,858,000Source | — | — | — |
| Operating ExpensesUSD | 83,512,000Source | 144,070,000Source | 126,135,000Source | 83,634,000Source |
| Research and Development ExpenseUSD | 61,979,000Source | 118,085,000Source | 102,546,000Source | 62,713,000Source |
Filing attachments
bmea-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 bmea-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes ("T2D"); data expected in the first quarter of 2027 • Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists ("GLP…
Read attachment ↗bmea-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 bmea-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights • Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12‑week clinical dosing that has been used to date • Topline data reported from the Phase II COVALENT-112 clinical trial of icovamenib in type 1 diabetes (“T1D”), supporting proposed mechanism of ac…
Read attachment ↗d142809dex991.htm · 8-K · 2026-04-28
EX-99.1 2 d142809dex991.htm EX-99.1 EX-99.1 COVALENT-112 Topline Results BIOMEA FUSION CONFERENCE CALL 28 APRIL 2026 Icovamenib in Type 1 Diabetes Exhibit 99.1 Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve known and unknown risks, uncertainties, and other factors that may cause the actual …
Read attachment ↗bmea-ex99_1.htm · 8-K · 2026-03-24
EX-99.1 2 bmea-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights • Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026 • Completed 52-week follow-up from Phase II trial COVALENT-112 (icovamenib in type 1 diabetes) with data expected in the second quarter of 2026 • Initiated Phase I trial enrollment of G…
Read attachment ↗